[Seminar] Chronic lymphocytic leukaemia

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in the past two decades have led to the development of new prognostic tools and novel targeted therapies that have improved clinical outcome. Chronic lymphocytic leukaemia is the most common type of leukaemia in developed countries, and the median age at diagnosis is 72 years. The criteria for initiating treatment rely on the Rai and Binet staging systems and on the presence of disease-related symptoms. For many patients with chronic lymphocytic leukaemia, treatment with chemotherapy and anti-CD20 monoclonal antibodies is the standard of care.

Source: LANCET - February 21, 2018 Category: General Medicine Authors: Michael Hallek, Tait D Shanafelt, Barbara Eichhorst Tags: Seminar Source Type: research